Omeros Corporation (NASDAQ:OMER) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Omeros Corporation (NASDAQ:OMER) have received a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $40.3333.

Several equities research analysts have weighed in on OMER shares. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Omeros in a research report on Thursday, May 14th. Zacks Research raised shares of Omeros from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 2nd. Weiss Ratings lowered shares of Omeros from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, June 2nd. Wall Street Zen lowered shares of Omeros from a “buy” rating to a “hold” rating in a research note on Sunday. Finally, D. Boral Capital restated a “buy” rating and set a $36.00 price target on shares of Omeros in a report on Tuesday, April 21st.

Insider Activity at Omeros

In other Omeros news, Director Thomas J. Cable sold 7,500 shares of the business’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $11.61, for a total value of $87,075.00. Following the completion of the transaction, the director owned 35,067 shares in the company, valued at $407,127.87. The trade was a 17.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 12.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Omeros

Several institutional investors have recently added to or reduced their stakes in OMER. Acadian Asset Management LLC purchased a new stake in Omeros in the first quarter valued at $357,000. XTX Topco Ltd purchased a new stake in shares of Omeros in the second quarter valued at about $191,000. Invesco Ltd. raised its holdings in shares of Omeros by 34.1% in the second quarter. Invesco Ltd. now owns 116,688 shares of the biopharmaceutical company’s stock valued at $350,000 after buying an additional 29,644 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of Omeros by 15.1% in the second quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company’s stock valued at $2,224,000 after buying an additional 97,224 shares during the last quarter. Finally, Sei Investments Co. purchased a new stake in shares of Omeros in the second quarter valued at about $40,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Stock Performance

Shares of NASDAQ OMER opened at $9.79 on Monday. The stock has a 50 day moving average price of $12.26 and a 200 day moving average price of $11.84. The firm has a market capitalization of $708.60 million, a price-to-earnings ratio of 13.99 and a beta of 2.52. Omeros has a 52-week low of $2.95 and a 52-week high of $17.65.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.16. The business had revenue of $9.89 million for the quarter, compared to analyst estimates of $4.19 million. Analysts forecast that Omeros will post -0.94 earnings per share for the current year.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.